You are here

Novartis gets creative in pricing next-generation cancer therapy

Its medicine is for a severe form of cancer in young people, known as acute lymphoblastic leukaemia


NOVARTIS AG, set to beat Kite Pharma Inc to the finish line in one of the most promising new areas of cancer research, is examining how to price a revolutionary therapy patients will need to take just once.

The US Food and Drug Administration is likely to rule in early...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to